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ABSTRACT
Objectives: This study aims to investigate the clinical value of uric acid in predicting adverse pregnancy outcomes (APOs) 
of women with hypertensive disorders of pregnancy. 
Material and methods: A total of 180 pregnant women with HDP from September 2015 to January 2017 were selected 
for this study. These subjects were classified into two groups, according to serum uric acid level: high UA group (n = 137) 
and normal UA group (n = 43). In addition, 180 healthy pregnant women were selected and assigned as the control group 
(n = 180). The monitored biochemical indices and APOs in these three groups were analyzed. Furthermore, non-conditional 
logistic regression analysis was performed to determine influencing factors of APOs in women with HDP and hyperuricemia. 
Results: The non-conditional multi-factor logistic regression analysis revealed that HUA (SUA > 357 umol/L) is the risk factor 
of APOs in women with HDP (OR = 1.258, P < 0.05). 
Conclusions: Women with HDP and HUA are often accompanied with a variety of abnormal biochemical indicators, and 
is correlated with the severity of the disease and APOs. 
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INTRODUCTION
In China, hypertensive disorders of pregnancy (HDP) 
still remains as one of the leading causes of maternal and 
perinatal morbidity and mortality. In the present study, we 
aimed to provide our expert evidence that hyperuricemia 
(HUA) in women with HDP may exert an adverse influence 
on their pregnancy and perinatal outcomes, and this effect 
is independent of gestational age, preeclampsia and other 
factors. However, it remains controversial worldwide that 
uric acid (UA) levels are correlated to HDP. Stander H. F. and 
Cadden J. F. [1] first discovered the correlationbetween HUA 
and preeclampsia in pregnant women. Following this dis-
covery, Paula L. G. [2] conducted a large-scale prospective 
multi-center study in 2008, and pointed out that serum uric 
acid (SUA) level was correlated to the perinatal prognosis of 
patients with HDP. In 2011, Bellomo G. et al. [3] considered that 
UA was a reliable indicator for predicting the development 
of HDP to preeclampsia and preterm birth, and this played 
an important role in pathology in preeclampsia. In addition, 
in 2016, Elmas O. et al. [4] conducted a study to determine 
the correlation between hypertension and plasma UA, and its 
predictive capacity in severe preeclampsia. In the same year, 
Shruti Agrawal [5] also emphasized the value of UA in his risk 
prediction model for predicting adverse maternal outcomes 
in women with HDP. However, the importance of monitoring 
UA levels in pregnant women remains controversial. In 2012, 
through a retrospective cohort study, Hawkins T. L. et al. [6] 
found that elevated UA levels in pregnant women with HDP 
had no obvious effect on maternal outcome. This conclu-
sion was supported by another study published in China in 
2016 [7]. The author, Chen Q, suggested that SUA may not 
be involved in the development of preeclampsia, and there-
by could not be a reliable marker to predict the incidence 
of adverse pregnancy outcomes (APOs). Despite all these 
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controversial evidences, our study aims to determine whether 
careful monitoring of UA levels for pregnancies complicated 
by HDP could improve long-term maternal, perinatal and 
pediatric outcomes.
Gestation is a normal physiological process, and HDP, in-
cluding gestational hypertension, preeclampsia (from mild to 
severe), chronic hypertension complicated by preeclampsia 
and chronic hypertension in pregnancy, is a special disease 
that occurs during pregnancy. This disease is complex and 
fast-changing, and physiological changes during delivery and 
after birth, as well as various pessimal stimuli, may exacerbate 
the disease. HDP is one of the main causes of maternal and 
neonatal mortality, and it is very important to closely evalu-
ate and monitor this during the antenatal, intrapartum and 
postnatal periods [8]. In this study, the authors conducted 
a retrospective analysis on 180 pregnant women with HDP, 
and investigated the APOs of those women, in order to de-
termine the clinical value of UA for HDP patients.
MATERIAL AND METHODS
Research subject: From September 2015 to January 
2017, 180 postpartum women with HDP in the medical 
intensive care unit (MICU) were studied. All patients were 
diagnosed through clinical examination according to the 
Guidelines for Diagnosis and Treatment of Hypertensive 
Disordersof Pregnancy (2012) [8], and patients with chronic 
liver and kidney diseases and diabetes were excluded from 
the study. The age of these patients were between 24 and 
39 years old, and the average age was 33.1 ± 2.5 years old. 
The gestation period was 36–42 weeks, with an average 
gestation period of 38.1 ± 1.9 weeks. These 180 women 
were divided into two groups, according to SUA levels: HUA 
group (n = 137), and normal UA group (n = 43). In addition, 
another 180 healthy pregnant women were selected and 
assigned as the control group (n = 180). The age of the 
women in the control group was between 23 and 40 years 
old, with an average age of 32.9 ± 2.6 years old. Furthermore, 
the gestation period of women in the control group was 
within 35–42 weeks, with an average of 38.3 ± 1.8 weeks. The 
difference in average age between the study groups (HUA 
group and normal UA group) and the control group was not 
statistically significant (P > 0.05).
Methods
The SUA levels of pregnant women in the study groups, 
as well as other indicators such as total protein, albumin, 
GBT, GOT, LDH, creatinine, BUN, TG, TC, HDL-C and LDL-C, 
were measured.
HUA diagnostic criteria [9]: HUA was considered when 
UA > 357 umol/L (6.0 mg/DL). Low birth weight (LBW) infants 
are newbornswith a weight < 2,500 g, according to Obstetrics 
(8th Edition) [10]. 
Test method
Three mL of venous blood was drawn from fasted preg-
nant women early in the morning after theywereadmitted 
in the ward. Blood biochemistry tests were performed us-
ing an Olympus AU 2700 Analyzer (Japan), and SUA was 
determined according to manufacturer’s instructions and 
protocol using the urate oxidase-peroxidase coupled en-
zyme system.
Statistical method
SPSS 20.0 was used for the statistical analysis of the data, 
and the PASS software was used to estimate the minimum 
sample size. First, normal distributionof all measurement 
data wasevaluated. If the data were normally distributed, 
the findings were expressed as x ± standard deviation (SD). 
For comparing two samples, t-test is adopted for homoge-
neity of variance, while an improved t-test was adopted 
for heterogeneity of variance. One-way analysis of vari-
ance (ANOVA) was adopted for comparing more than two 
groups, while the least significant difference (LSD) method 
was adopted for comparing two groups. Chi-square test was 
used for counting data, and non-conditioned multi-factor 
logistic regression analysis was used for correlation analy-
sis. P < 0.05 was considered statistically significant. 
RESULTS
SUA level and the incidence of HDP was significantly 
higher in the HUA group than in control group. The average 
level of SUA was 340.0 ± 119.6 μmol/L and 295.8 ± 81.7 μmol/L 
in the HUA group and control group, respectively; and the 
difference was statistically significant (P < 0.05, Tab. 1).
The correlation between HDP and HUA, and the patient’s 
condition are presented in Table 2. These results revealed 
that the difference in total protein, albumin, GBT, GOT, LDH, 
creatinine, BUN, TG, TC, HDL-C and LDL-C between the HUA 
group and control group was statistically significant (P < 0.05).
Common APOs include preterm birth, LBW, fetal distress, 
asphyxia, stillbirth, placental abruption, disseminated intra-
vascular coagulation (DIC), liver dysfunction, and serosal 
fluid and postpartum hemorrhage. The analysis of the ma-
ternal and perinatal adverse outcomes in the HUA group in 
the late trimester is presented in Table 3, and the difference 
with control group was statistically significant (P < 0.05). The 
Table 1. Comparison of average blood uric acid level and incidence 
of HUA between HDP group and control group
Group Number SUA(x ± s, umol/L) HUA [(%)]
HDP 180 340. 0 ± 119. 6 69 (76.7)
Control 180 295. 8 ± 81. 7 14 (15.6)
p value < 0.05 < 0.05
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correlation analysis shows that SUA is positively correlated 
with the incidence of APOs, as presented in Table 4. This 
demonstrates that higher UA is positively correlated with the 
incidence of APOs. This proves that the clinical evaluation of 
UA levels in women with HDP and HUA is of high significance 
for avoiding and reducing the incidence of APOs.
Table 2. Comparison of biochemical test indexes among three groups x ± S
Group Number Total protein (g/L) ALB (g/L) GBT (U/L) GOT (U/L) LDH (U/L)
A 137 47.2 ± 4.7ab 28.2 ± 3.7ab 37.5 ± 14.5ab 40.4 ± 12.1ab 262.3 ± 100.9ab
B 43 53.6 ± 4.9a 29.1 ± 4.0a 22.7 ± 16.7a 29.3 ± 18.3a 194.5 ± 98.6a
Control 180 62.7 ± 3.2 32.2 ± 3.7 15.6 ± 8.6 20 ± 10.6 135.8 ± 44.9
p value  < 0.05  < 0.05  < 0.05  < 0.05  < 0.05
Group Creatinine (umol/L) BUN (mmol/L) FBG (mmol/L) TG (mmol/L)
A 71.9 ± 22.7ab 4.9 ± 1.9ab 5.1 ± 1.3 4.6 ± 1.8ab
B 65.7 ± 31.9a 3.8 ± 1.5a 5.0 ± 0.9 2.7 ± 1.2 
Control 46.9 ± 11.0 2.9 ± 0.9 5.1 ± 0.8 2.6 ± 1.7
p value  < 0.05  < 0.05 >0.05  < 0.05
Group TC (mmol/L) HDL-C (mmol/L) LDL-C (mmol/L)
A 7.6 ± 2.1ab 1.7 ± 0.5a 3.3 ± 1.4ab
B 5.7 ± 1.6a 1.6 ± 0.7a 2.6 ± 0.7 
Control 5.1 ± 1.7 2.2 ± 0.9 2.1 ± 0.8
p value  < 0.05  < 0.05  < 0.05
a vs Control Group, P < 0.05; b vs Control Group, P < 0.05
Table 3. Comparison of APOs among three groups [cases (%)]
Group Number Preterm birth Fetal distress Asphyxia Stillbirth LBW
A 137 26 (3 7.7) a b 4 (5.8) a b 3 (4.3) a b 1 (1 .4) a 25 (36.2) a b
B 43 3 (1 4.3) a 1 (4.8) a 1 (4.8) a 0 (0.0) 3 (14.3) a
Control 180 2 (2.2) 1 (1.1) 0 (0.0) 0 (0.0) 2 (2.2)
x2 32,893 17,285 17,013 14,017 31,567
p value < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
Group Number Placental abruption DIC
Liver
dysfunction
Postpartum 
hemorrhage
Serosal
fluid
A 137 24 (34.8)a b 3 (4.3)a b 6 (8.7)a 18 (26.1)a b 8 (11.6)a b
B 43 4 (19.0)a 0 (0.0) 2 (9.5)a 2 (9.5)a 3 (14.3)a
Control 180 3 (3.3) 0 (0.0) 2 (2.2) 4 (4.4) 1 (1.1)
x2 36,463 17,693 15,654 31,493 32,893
p value < 0.05 < 0.05 < 0.05 < 0.05 < 0.05
a vs Control, P < 0.05; b vs Group B, P < 0.05
Table 4. Non-conditional multi-factor logistic regression analysis of women with HDP
Variables β SE Waldx2 df P OR 95% CI
Constant term 0.497 0.194 27.810 1 0.000 0.441 –
Hyperuricemia 0.228 0.124 4.703 1 0.035 1.258 1.038~1.526
Preeclampsia 0.886 0.328 12.671 1 0.000 2.477 1.657~3.572
Pregnant-duration 0.189 0.079 6.171 1 0.026 1.218 1.069~1.478
“–” refers to the items undetected
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DISCUSSION
As a common obstetric complication, HDP is one of the 
key causes of maternal and perinatal morbidity and mor-
tality. The pathophysiological mechanisms includearterial 
spasm, blood concentration, microcirculatory impairment 
and subclinical disseminated intravascular coagulation 
(DIC). The reduced blood volume and inadequate organ per-
fusion resulting from blood vessel spasms and the increased 
permeability of blood vessels may cause maternal and fetal 
injury, and even death. The clinical syndromes of organ dam-
age include proteinuria, renal insufficiency, hepatic and 
hematologic diseases and fetal growth restriction [10]. Al-
though the etiology of HDP has not been exactly identified, 
superficial placental implantation resulting from the release 
of inflammatory cytokines in maternal blood circulation and 
other anti-angiogenesis factors is an important cause. In 
addition, the increased level of UA is one of abnormallabo-
ratory indexes in the treatment of HDP.
As an end product of human purine metabolism, UA 
has two sources in human body: (1) the decomposition 
and catabolism of nucleic acid in the body (approximately 
80%), and (2) the decomposition of food containing purine 
or nucleoprotein (approximately 20%). UA is excreted in 
three ways: (1) after four steps including glomerular filtra-
tion, proximal renal tubular reabsorption, proximal renal 
tubular secretion in the distant part, and reabsorption after 
secretion, and UA is eventually discharged with urine (ap-
proximately 70%); (2) entering into the intestinal cavity 
through the secretion of intestinal mucosal cells, the uricase 
in intestinal bacteria can transform UA into allantoin, and is 
discharged with urine (approximately 30%); (3) decompo-
sition in white blood cells (approximately 2%) [11, 12]. UA 
is one kind of colorless and tasteless water-soluble weak 
organic acid, which has low solubility in the urinary system 
with a pH value between 5.0 and 6.0, and lower physical 
solubility in blood circulation. In early pregnancy, SUA con-
centration is lower than that of non-pregnant women due 
to increasedblood volume, renal blood flow and glomerular 
filtration rate, and the elevatedexcretion of UA stimulated by 
estrogen caters. However, from the second trimester, SUA 
begins to increase and eventually reaches normal levels 
during full-term pregnancy. A low UA concentration has the 
anti-oxidation effect, but it may cause HUA due to increas-
ing SUA when UA metabolism disorder occurs, increasing 
UA or decreasing excretion; and this may lead to a series of 
pathological and physiological changes: (1) UA can separate 
crystals out and deposit in the blood vessel wall, which 
may directly damage the intima; (2) UA can promote adhe-
sion and aggregation, as well as the thrombosis of blood 
platelets; (3) UA can increase oxygen-derived free radicals, 
and induce functional damage of the mitochondria and lys-
osomes, which promotes the aggregation of granulocytes in 
vascular endothelial cells; (4) UA promotes low density lipo-
protein cholesterol (LDL-C) oxidation and produces toxicity 
in endothelial cells, which may cause the apoptosis of vascu-
lar smooth muscle cells, and further vascular inflammatory 
reaction [13, 14]. In conclusion, elevated SUA not only causes 
vascular endothelial disorder and decreasesthe synthesis of 
nitric oxide, but also activates the renin-angiotensin system 
in the body, which can easily result in high blood pressure. 
Therefore, it can be concluded that SUA is a strong oxidant 
that can promote the production of oxygen-derived free 
radicals. However, it is a double-edged sword. Elevated 
SUA is common in preeclampsia, and it can be detected 
earlier than the diagnosis of hypertension, proteinuria and 
preeclampsia. In view of its destructive effect on vascular 
endothelial cells, this can be used to reveal the significant 
role of UA in the pathogenesis of HDP [15].
Since the correlation between HUA and preeclampsia 
in pregnant women was first discovered by Stander J. F. and 
Cadden H. F. [1], SUA has been considered as an important 
marker in the early diagnosis of preeclampsia. However, 
since urinary proteins can better reflect the renal damage of 
patients with HDP, the diagnostic value of HUA has remained 
controversial. In a large-scale prospective multi-center study 
in 2008, Paula L. G. pointed out that SUA level was correlated 
to the perinatal prognosis of patients with HDP [2]. In 2011, 
Bellomo G. et al. [3] considered that UA was a reliable indica-
tor for predicting the development of HDP for preeclampsia 
and preterm birth, and it played an important role in pathol-
ogy in preeclampsia. Continuous high levels of UA may 
trigger a series of ischemic injuries, because it may decrease 
nitric oxide concentration, obstruct placental vascular re-
modeling and reduce intramuscular perfusion. Hence, UA is 
of significant clinical value in predicting perinatal outcome. 
This is consistent with the conclusions in this study. In 2012, 
Hawkins T. L. et al. [6] found through a retrospective co-
hort study that increased UA in pregnant women with HDP 
could lead to higher risk of adverse fetal outcomes such as 
small-for-gestational age infants and premature birth, but 
it had no obvious effect on maternal outcome. However, 
with the increase in UA of women with preeclampsia, the 
risk of APOs for both mothers and infants would significantly 
increase. This shows that SUA is a marker of predicting the 
APOs of patients with HDP. In addition, it was also found 
that the coincidence of increased incidence of preterm birth 
and decreased natural childbirth shows that maternal and 
fetal complications resulting from HUA may accelerate the 
need for termination of pregnancy. Other studies have 
also focused on the correlation between UA and fetal birth 
weight [16]. In a cohort study involving 1,487 cases, Joel R. 
[17] also confirmed Hawkins’ conclusion, wherein he con-
sidered that the corrected UA according to gestational age 
can better predict adverse perinatal outcomes than random 
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UA value, and its sensitivity and specificity were 93% and 
27%, respectively. Through comparing the perinatal period 
information of women who have normal blood pressure, 
but respectively deliver small-for-gestational age infants 
and infants of right age, Akahori Y. et al. [18] found that the 
levels of hematuria acid, creatinine and blood pressure of 
the former were obviously higher than those of the latter. 
Increased SUA is correlated to mild kidney function damage 
and LBW infants. Multi-factor regression analysis revealed 
that the level of SUA in pregnant women is an independent 
risk factor of LBW infants. However, the UA level of pregnant 
women who deliver very light birth weight infants has no 
correlation with birth weight, but it has a positive correla-
tion with creatinine. In the meantime, the fluctuation of SUA 
levels in pregnant women who deliver small-for-gestational 
age infants and infants of the right age is similar to the 
difference in the UA level of metabolic syndrome and the 
normal control group. This shows that the change in UA 
level may be correlated to fetal growth. In order to timely 
and effectively cure pregnant women with preeclampsia, 
Payne B. A. [19] designed an integrated risk prediction scor-
ing system for women with preeclampsia, in which the UA 
value is included. One shortcoming of Payne’s study is that 
he excluded women with HDP, and only studied pregnant 
women with preeclampsia [20]. Different from Payne’s study, 
this study includes pregnant women with preeclampsia, 
chronic hypertension and HDP, and draws the basic con-
sistent conclusion with Paula L. G., Hawkins J. and Joel R.
Although hyperuricemia is commonly seen in wom-
en with preeclampsia, a systematic review of five studies 
concluded that measurement of SUA concentration be-
fore 25 weeks of gestation was not useful for predicting 
which women would develop preeclampsia. One study 
[21] used a rise in SUAconcentration above baseline level 
as the criterion for a positive test result, while the other 
four studies used threshold values above 3.5 to 4 mg/dL 
(0.21 to 0.24 mmol/L) as the cut-off for a positive test result. 
Sensitivities ranged from 0 to 56 percent and specificities 
ranged from 77 to 95 percent.
Similarly, a second systematic review [22] concluded 
that SUA measurement was not useful for predicting de-
velopment of complications in women with preeclampsia. 
However, SUA may be useful in predicting the length of 
the latency period from diagnosis to delivery. The author of 
another article [23] showed that admission uric acid levels 
correlate with the length of expectant management in pre-
term patients with preeclampsia. Pregnancy prolongation 
for > 1 week is significantly more likely in patients with low 
and medium uric acid levels at the time of admission. Uric 
acid levels may be helpful in assessing disease severity and 
counseling preeclamptic patients regarding likelihood of 
extended expectant management.
In conclusion, this study argues that increased UA levels 
would represent a higher incidence of women’s perinatal 
adverse outcomes, fetal preterm birth, fetal distress, LBW 
infants and perinatal mortality. Although due to limited 
articles to give more evidence to verify the importance 
of SUA test in pregnant women with hypertension, many 
professional bodies such as the American College of O&G 
do not advocate laboratory and imaging screening tests 
but rather a detailed medical history to assess a patient’s 
risks of developing pre-eclampsia. However, we believe for 
the patients with increased SUA, when UA > 357 mmol/L, 
maternal and fetal health should be closely monitored. In 
addition, through an unconditional multi-factor logistic 
regression analysis and after the correction of confound-
ing factors, it was shown that HUA is a high risk factor for 
women with HDP (OR = 1.258), and this further proves that 
HUA in the women with HDP may exert an adverse influ-
ence on their pregnancy and perinatal outcomes, and this 
effect is independent of gestational age, preeclampsia and 
other factors.
No evidence can prove that APOs of women with HDP 
can be reduced through lowering SUA. However, given 
the close link between HUA and the adverse prognosis of 
vascular, heart, kidney and other systematic organs, and the 
possible result of adverse maternal outcome, it may be one 
effective measure for high-risk pregnant women to publicize 
health education, advocate low-purine and low-fat diet, and 
control SUA levels.
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